Literature DB >> 7929850

Chemiluminescent and enzyme-linked immuno assays for sensitive detection of human IFN-gamma.

S Alkan1, C Akdis, H Towbin.   

Abstract

We have produced and characterized 4 mAbs to human IFN-gamma and established sensitive, non-radioactive immuno-assays. The first two assays use microtiter plates as the solid phase and enzymes or chemiluminescence (acridinium ester) for development. The use of chemiluminescence instead of peroxidase increased the sensitivity of the assay by a factor of about 75. The third and the fourth assays utilize polystyrene beads as the solid phase and enzymes or acridinium ester for development. The use of beads also increased the sensitivity of detection. The most sensitive IFN-gamma detection was achieved by the combination of bead with acridinium ester. In this configuration we were able to detect about 0.2 pg/ml IFN-gamma (1/250th of a unit). These chemiluminescent immunoassays (CLIA) appear to be more sensitive than existing ELISAs or radioimmunoassays and may find new application areas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929850     DOI: 10.1080/15321819408009574

Source DB:  PubMed          Journal:  J Immunoassay        ISSN: 0197-1522


  3 in total

1.  Evaluation of a tuberculosis whole-blood interferon-γ chemiluminescent immunoassay among Chinese military recruits.

Authors:  Xueqiong Wu; Ying Hou; Yan Liang; Junxian Zhang; Yourong Yang; Lan Wang; Chuiying Zhang
Journal:  Mol Diagn Ther       Date:  2011-12-01       Impact factor: 4.074

2.  Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro.

Authors:  C A Akdis; M Akdis; T Blesken; D Wymann; S S Alkan; U Müller; K Blaser
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

3.  T cell receptor (TCR) engagement in apoptosis-defective, but interleukin 2 (IL-2)-producing, T cells results in impaired ZAP70/CD3-zeta association.

Authors:  A G Sahuquillo; A Roumier; E Teixeiro; R Bragado; B Alarcón
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.